# GP Healthcare Capital

> GP Healthcare Capital is a VC fund in Shanghai backing Biotechnology and Health Care. See 10 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Shanghai, China
- Total investments: 10
- Last investment: Jul 2023
- Lead investor: 30%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/gp-capital-co.-ltd/
- Website: https://healthservice.gpcapital.com.cn/index.php?m=content&c=index&a=lists&catid=93

GP Healthcare Capital is an investment firm that is mainly engaged in equity investment management, assets management, and enterprise management consulting. It focuses on investing companies in the biotechnology industry. GP Healthcare Capital was founded in 2015 and is headquartered in Shanghai, China.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 60% |
| Health Care | 4 | 40% |
| Medical | 3 | 30% |
| Therapeutics | 2 | 20% |
| Manufacturing | 2 | 20% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 4 | 40% |
| Series A | 2 | 20% |
| Series C | 2 | 20% |
| Series D | 1 | 10% |
| Venture - Series Unknown | 1 | 10% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 9 | 90% |
| United States | 1 | 10% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Stand Group | Stand Group provides diversified testing and R&D services to national and global health, economic, and social development markets. |  | Series C | Jul 27, 2023 |  |
| Kingwills New Materials | The main business of "Qingyun New Materials" is to develop, produce and sell flash-spun metamaterial Kunlun® Hypak® , which is a high-strength, waterproof and breathable special fiber material that is arranged in the form of non-woven fabrics. | $14.2M | Series B | May 18, 2023 |  |
| Lingyu Technology | Lingyu Technology is a financial digital intelligent solution service provider. |  | Series A | Nov 28, 2022 |  |
| Yuntian Semiconductor | Yuntian Semiconductor is a semiconductor firm that develops TGV technology, filter wafer-level 3-D packaging technology, and IPD technology. |  | Series B | Dec 06, 2021 |  |
| TransThera Biosciences | TransThera Biosciences is a biotech company that focuses on the discovery and development of small-molecule new drugs. Its research and business strategies zero in clear unmet medical needs in oncology and inflammatory diseases through internal research and open innovation. The company was founded in 2016 and is headquartered in Nanjing, Jiangsu. | $100M | Series D | Jul 25, 2021 |  |
| Jenscare Biotech | A Biotech Company based In Ningbo. |  | Venture - Series Unknown | May 28, 2021 |  |
| GenomiCare Biotechnology | GenomiCare Biotechnology (Shanghai) Co., Ltd is a Chinese precision cancer medicine service company, providing personalized clinical precision medicine solutions and medical resources for Chinese cancer patients and doctors. | $30M | Series A | Dec 18, 2018 |  |
| Beijing Allcure Medical Technology | Beijing Allcure Medical Technology Co., Ltd. applies mdaccAutoPlan® radiotherapy plan algorithm and aims at promoting medical treatment communication,trying to improve the survival rate of Chinese tumor patients through internet, big data, cloud computing and other advanced methods. | $99.2M | Series B | Jul 24, 2018 |  |
| MicuRx Pharmaceuticals | MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient infrastructure and scientific resources available inChina. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China. | $55M | Series C | Sep 26, 2016 |  |
| Adagene | Adagene is a clinical-stage biotech company that specializes in developing immuno-oncology antibodies against novel epitopes. It has its proprietary Smart Antibody Technology, which increases success rates, substantially accelerates time to market, and reduces the costs associated with developing a therapeutic antibody. | $28M | Series B | Jan 29, 2016 |  |

10 of 10 investments shown.

## Co-investors
- [CICC](https://shizune.co/investors/profile/cicc) — VC Fund, 2 deals together
- [GL Ventures LLC](https://shizune.co/investors/profile/gl-ventures-llc) — VC Fund, 2 deals together
- [3E Bioventures](https://shizune.co/investors/profile/3e-bioventures) — VC Fund, 1 deal together
- [ABC International](https://shizune.co/investors/profile/abc-international) — VC Fund, 1 deal together
- [Oriental Yuhong](https://shizune.co/investors/profile/beijing-oriental-yuhong-waterproof-technology) — VC Fund, 1 deal together
- [CD Capital](https://shizune.co/investors/profile/cd-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does GP Healthcare Capital invest in?

GP Healthcare Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 10 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did GP Healthcare Capital last invest?

The most recent investment recorded for GP Healthcare Capital closed in Jul 2023. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co